Amgen Surpasses Expectations with Strong Q2 Results and Raised Guidance
TL;DR Summary
Amgen reported strong Q2 earnings exceeding expectations but saw declines in key product sales, leading to a drop in after-hours stock trading. The company highlighted growth in products like Uplizna and Tepezza, and raised its full-year guidance despite mixed quarterly results.
- Will Amgen, Already Above Its 50-Day Line, Break Out? Investor's Business Daily
- Amgen quarterly results beat Wall Street estimates Yahoo Finance
- Amgen Posts Higher Profit, Revenue On Sales Growth Among Products The Wall Street Journal
- Amgen beat Q2 revenue and profit, stock trades flat (AMGN) Seeking Alpha
- Amgen Lifts 2025 Guidance After Drug Sales Beat Expectations Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
90%
413 → 41 words
Want the full story? Read the original article
Read on Investor's Business Daily